Home / Health / Kids' Weight-Loss Drugs Show Promising Results
Kids' Weight-Loss Drugs Show Promising Results
18 Jul
Summary
- Weight-loss drugs studied in children aged six to 17.
- Semaglutide use led to an average loss of nearly 2st 12lb.
- Children's quality of life and health markers improved.
New research indicates that weight-loss drugs, including semaglutide (Wegovy, Ozempic), may offer significant benefits for children aged six to 17 struggling with obesity. Analysis of nine studies involving 756 children found substantial weight loss, averaging 11lb (5kg) overall and nearly 2st 12lb (18kg) with semaglutide. These GLP-1 medications were associated with reduced BMI, lower blood pressure, and improved quality of life.
While current UK availability of Wegovy is for private use in those aged 12 and above, clinical trials are ongoing to evaluate these drugs for the 6-12 age group. Experts emphasize that regulatory approval hinges on benefits clearly outweighing potential risks. In the UK, specialist NHS clinics have treated over 6,000 children since 2021, with a quarter under nine years old, highlighting the widespread need for effective obesity interventions in younger populations.
